These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 29977914)
1. Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. Chen D; Lin X; Gao J; Shen L; Li Z; Dong B; Zhang C; Zhang X Biomed Res Int; 2018; 2018():5813292. PubMed ID: 29977914 [TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
3. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241 [TBL] [Abstract][Full Text] [Related]
4. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765 [TBL] [Abstract][Full Text] [Related]
6. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434 [TBL] [Abstract][Full Text] [Related]
7. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930 [TBL] [Abstract][Full Text] [Related]
8. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019 [TBL] [Abstract][Full Text] [Related]
9. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Garcia TB; Fosmire SP; Porter CC Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378 [TBL] [Abstract][Full Text] [Related]
10. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076 [TBL] [Abstract][Full Text] [Related]
11. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. Matheson CJ; Casalvieri KA; Backos DS; Reigan P ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531 [TBL] [Abstract][Full Text] [Related]
12. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Wang B; Sun L; Yuan Z; Tao Z Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094 [TBL] [Abstract][Full Text] [Related]
13. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma. Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780 [TBL] [Abstract][Full Text] [Related]
14. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan. Yin Y; Shen Q; Tao R; Chang W; Li R; Xie G; Liu W; Zhang P; Tao K Mol Med Rep; 2018 Feb; 17(2):3344-3349. PubMed ID: 29257266 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398 [TBL] [Abstract][Full Text] [Related]
16. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815 [TBL] [Abstract][Full Text] [Related]
17. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Ford JB; Baturin D; Burleson TM; Van Linden AA; Kim YM; Porter CC Oncotarget; 2015 Sep; 6(29):28001-10. PubMed ID: 26334102 [TBL] [Abstract][Full Text] [Related]
18. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer. Sand A; Piacsek M; Donohoe DL; Duffin AT; Riddell GT; Sun C; Tang M; Rovin RA; Tjoe JA; Yin J Cancer Lett; 2020 Mar; 472():119-131. PubMed ID: 31866466 [TBL] [Abstract][Full Text] [Related]
19. HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer. Dou Z; Qiu C; Zhang X; Yao S; Zhao C; Wang Z; Chu R; Chen J; Chen Z; Li R; Wang K; Liu P; Liu C; Song K; Kong B Int J Biol Sci; 2022; 18(3):1188-1210. PubMed ID: 35173547 [TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]